Please assess the completion status of the following clinical trial:

Trial Title: Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.~* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.~* age \> 18~* Karnofsky performance status \> 60%~* Measurable disease on clinical exam or by RECIST criteria~* One prior platinum-based systemic chemotherapy regimen for advanced disease is allowed but not required. Chemotherapy administered as a radiosensitizer in conjunction with primary radiotherapy is not considered a systemic chemotherapy regimen and is also allowed. Patients eligible for a higher priority study will be excluded.~* Life expectancy \> 6 weeks~* Peripheral neuropathy ≤ Grade 2 by CTC 3.0 criteria~* Women of child-bearing potential must have a negative pregnancy test~* Adequate hematopoietic function defined as: ANC ≥ 1500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 8 g/dL.~* Adequate renal and hepatic function defined as: Bilirubin ≤ 1.5 times upper limit of normal (ULN); SGOT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 2.5 times ULN; Creatinine ≤ 2 times ULN.~Exclusion Criteria~* Patient has hypersensitivity to bortezomib, boron or mannitol.~* Female subject is pregnant or breast-feeding.~* Patient has received other investigational drugs with 14 days before enrollment~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.~* Prior treatment with CAMPTOSAR or VELCADE~* More than one prior treatment for metastatic disease.~* Concurrent uncontrolled illness~* Ongoing or active infection~* History or active secondary cancer within the last 5 years, except for superficial basal cell skin cancers~* Psychiatric illness or social situation that would preclude study compliance.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).